Biotinylated Recombinant Human Cd44 Antigen (CD44) Protein (mFc-Avi), Active

Name: Biotinylated Recombinant Human Cd44 Antigen (CD44) Protein (mFc-Avi), Active
Brand: Beta LifeScience
SKU: BLC-05835P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Activity Measured by its binding ability in a functional ELISA. Immobilized Anti-CD44 Mouse Monoclonal Antibody at 2 μg/ml can bind Biotinylated human CD44, the EC 50 is 2.865-5.099 ng/ml. Biological Activity Assay

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Avi-tagged proteins, Biotinylated proteins, Car-nk targets proteins, Cluster of differentiation (cd) proteins, Featured biotinylated protein molecules, Featured cd protein molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Biotinylated Recombinant Human Cd44 Antigen (CD44) Protein (mFc-Avi), Active is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Endotoxin	Less than 1.0 EU/ug as determined by LAL method.
Activity	Measured by its binding ability in a functional ELISA. Immobilized Anti-CD44 Mouse Monoclonal Antibody at 2 μg/ml can bind Biotinylated human CD44, the EC 50 is 2.865-5.099 ng/ml.
Uniprotkb	P16070
Target Symbol	CD44
Synonyms	(CDw44)(Epican)(Extracellular matrix receptor III)(ECMR-III)(GP90 lymphocyte homing/adhesion receptor)(HUTCH-I)(Heparan sulfate proteoglycan)(Hermes antigen)(Hyaluronate receptor)(Phagocytic glycoprotein 1)(PGP-1)(Phagocytic glycoprotein I)(PGP-I)(LHR)(MDU2)(MDU3)(MIC4)
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	C-mFc-Avi
Target Protein Sequence	QIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFYTFSTVHPIPDEDSPWITDSTDRIP
Expression Range	21-220aa
Protein Length	Partial
Mol. Weight	51.0 kDa
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Cell projection, microvillus.
Database References	HGNC: 1681 OMIM: 107269 KEGG: hsa:960 STRING: 9606.ENSP00000398632 UniGene: Hs.502328
Tissue Specificity	Isoform 10 (epithelial isoform) is expressed by cells of epithelium and highly expressed by carcinomas. Expression is repressed in neuroblastoma cells.

Gene Functions References

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics. PMID: 29236307
we demonstrated that miR711mediated downregulation of CD44 expression inhibited EMT of gastric cancer cells in vitro and in vivo by downregulating vimentin protein expression and upregulating Ecadherin protein expression through transfection, qRTPCR and western blotting. PMID: 30226620
Expression levels of MACC1, CD44, Twist1, and KiSS-1 are related to duration of overall survival among patients with colonic adenocarcinoma. PMID: 30021598
miR-218-5p was downregulated in invasion front cells and negatively regulates oral squamous cell carcinoma invasiveness by targeting the CD44-ROCK pathway. PMID: 29990854
our study demonstrated that miR-520b inhibits the malignancy of HNC through regulation of cancer stemness conversion by targeting CD44. PMID: 28515423
The work identified two new host factors that may act as receptors for P. falciparum during invasion: CD44 and CD55. (Review) PMID: 29249333
Reports indicate that high CD44 expression in ascites tumor cells (ATC) correlates with CSC and EMT phenotype, both regulated by the tumor microenvironment through several signaling pathways, including the TGF-beta signaling pathway. PMID: 30142697
Data identified Twist1 and CD44 as novel REST targeted genes and provide new insight into the epigenetic regulation of Twist1 and CD44 by REST. PMID: 28256535
Data show increased CD44 levels in ovarian cancer patient samples correlated with enhanced expression of the mesenchymal spliced variant CD44s (standard) and a concurrent decrease in the epithelial variants (CD44v). Moreover, CD44s was upregulated upon TGFbeta1-induced EMT, which was mediated through the downregulation of the splicing factor, ESRP1. Overexpression of CD44s induced EMT, invasion, and chemoresistance. PMID: 29130517
The current evidence suggests that CD44 is an efficient prognostic factor in pancreatic cancer. PMID: 29683068
the CD44-NRF2 axis might be a promising therapeutic target for the control of stress resistance and survival of CD44(high) CSC population within breast tumors. PMID: 29729523
These results reveal a novel positive feedback loop involving CD44S and YAP1, in which CD44S functions as both an upstream regulator and a downstream effector of YAP1 in hepatocellular carcinoma. PMID: 29649630
CHI3L1 expression is a novel biomarker for the prognosis of gastric cancer and these findings have thus identified CHI3L1/CD44 axis as a vital pathway and potential therapeutic target in gastric cancer . PMID: 30165890
The selective binding of HA-CH-NP/siRNA to CD44-positive tumor endothelial cells. PMID: 29890852
Results showed that the expression of IGF1R appears to be highly correlated with the expression of ABCG2 in osteosarcoma and with the expression of CD44 in osteosarcoma patients under age of 10. PMID: 29892839
CD44 Polymorphisms are associated with Gastric Cancer. PMID: 29802692
verification of the presence of stem cell-like cells in the epithelial component through the immunopositivity to Oct-4 and CD44 in benign odontogenic lesions of variable biological behaviors PMID: 29971493
The genotypes CT, CT+TT, TT, and allele T in rs13347 of CD44 may be risk factors for breast cancer. PMID: 29748526
Peripheral blood lymphocyte subsets in patients with lung cancer are different from those in healthy people, and circulating CD44+ and CD54+ lymphocytes seem to be a promising criterion to predict survival in lung cancer patients undergoing chemotherapy PMID: 29148014
The minority of cancer stem cells would not be detected by immunohistochemistry using panCD44. PMID: 29682524
CD44 regulated TLR2 responses in human macrophages, whereby a reduction in CD44 levels or engagement of CD44 by its ligand (HA) or a CD44-specific Ab reduced NF-kappaB translocation and downstream proinflammatory cytokine production. PMID: 29196459
Our results suggested that CD44 expression could be used as a marker for the prediction of gastric cancer development, particularly in patients with precancerous gastric lesions carrying AG or GG, who were selected to surveillance follow-up for gastric cancer prevention. PMID: 29445738
CD44 polymorphism rs13347 acts as a risk factor for cancer, especially in Chinese, while the minor allele of polymorphism rs11821102 may be associated with a decreased susceptibility to cancer PMID: 28000766
ntermediate Molecular Mass Hyaluronan and CD44 interactions on PMNs potently elicit F-actin cytoskeleton polymerization and p38- and ERK1/2-MAPK phosphorylation to enhance PMN function. PMID: 28730511
CD44v9 in tumor specimens has potential as a novel indicator for identifying a cisplatin-chemoresistant population among urothelial cancer patients. CD44v8-10 contributes to reactive oxygen species defenses, which are involved in chemoresistance, by promoting the function of xCT, which adjusts the synthesis of glutathione. PMID: 29385995
CD44 standard isoform was especially upregulated after high-dose X-ray irradiation. PMID: 29106581
Upregulated miR-373 levels and simultaneously downregulated levels of CD44 and E-cadherin were noted in this study. PMID: 29307338
MiRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. PMID: 29094237
This study using syngeneic mouse models, which better model the disease in humans than conventional xenografts, suggests that NIR-PIT with anti-CD44-IR700 is a potential candidate for the treatment of Oral cavity squamous cell carcinoma PMID: 28923838
miR214 represses endogenous CD44 expression by targeting the 3'untranslated region in HeLa, Raji and Jurkat cells. PMID: 29138813
This analysis indicated that corilagin is mainly involved in the glycolysis pathway. Seahorse XF96 extracellular acidification rate analysis confirmed that corilagin inhibited glycolysis by downregulation of CD44 and STAT3 PMID: 28791374
an important role for HYAL2 in CD44 alternative splicing. PMID: 29162741
CD146 suppresses BC progression as a target of CD44-downstream signaling PMID: 29121955
based on our data, the markers CD44 and CD24 do not reflect the features of CSC and unfavorable prognosis and do not clarify the role and clinical significance of the immunophenotype CD44+/CD24-. PMID: 28967636
CD44s levels correlate with EGFR signature and predict poor prognosis in glioblastomas. PMID: 28716909
This study demonstrated that expression of CD44S and CD44 splice variants CD44V3, CD44V6, and CD44V10 was significantly higher in AD patients compared to non-AD controls PMID: 28550248
Network analysis of overlapping genes revealed the effects on tubulins (Tubb2a, Tubb3, Tubb4b), Nfe2l2, S100a4, Cd44, and Nfkb2, all of which are linked to TBI-relevant outcomes, including epileptogenesis and tissue repair PMID: 27530814
In obese patients, hepatic CD44 was strongly upregulated in NASH patients (p=0.0008) and correlated with NAFLD activity score (NAS) (p=0.001), ballooning (p=0.003), alanine transaminase (p=0.005) and hepatic CCL2 (p<0.001) and macrophage marker CD68 (p<0.001) expression. Correction of NASH was associated with a strong decrease in liver CD44(+) cells. PMID: 28323124
These findings suggest that CD44v and CD44s cells play differently important roles in the progression and metastasis of GBC and the isoform switch triggers epithelial-mesenchymal transition PMID: 28677740
Results suggest significant role of CD44 variants (rs13347, rs187115 and rs11821102) in modulating individual's cancer susceptibility in Asians (meta-analysis). PMID: 27521214
CD44v9 may be a good biomarker for prognosis prediction and for chemoprevention or biomarker-driven therapies only for Early Gastric Cancer, and it appeared to be associated with lymph node metastasis PMID: 25779358
Tunicamycin inhibited CD44s overexpression-associated cell migration. PMID: 29377347
Osteopontin and CD44 play important roles in the development and progression of meningioma and can be used as prognostic markers for tumor recurrence and progression as well as therapeutic targets for the development of new drugs. PMID: 29504367
CD24 and CD44 are upregulated in human pancreatic cancer compared to chronic pancreatitis and may be related to the development of pancreatic cancer. PMID: 28659655
our study results showed that CD44v6 is an important regulator of GC tumorigenesis, angiogenesis, and survival in an IL-6 mediated, pSTAT3-dependent manner PMID: 28507278
expressed by rheumatoid synovial fibroblasts in a MIF allele-dependent fashion and undergoes functional regulation and activation by autocrine/paracrine MIF PMID: 27872288
Circulating tumor cells expressing cytokeratin and tumor-initiating cell markers, including ALDH, CD133, and CD44, were identified in patients with pancreatic adenocarcinoma. These TIC-like CTCs were associated with poor prognosis after surgical resection and with an increased incidence of tumor recurrence PMID: 27789528
High CD44 expression is associated with renal cell carcinoma. PMID: 27588469
FAM83D promotes HCC recurrence by promoting CD44 expression and CD44+ CSCs malignancy. PMID: 27769048
Intraperitoneal enrichment of cancer stem-like cells, from ovarian cancer cell lines or primary ovarian tumor, provides a rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. PMID: 27655682

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.